GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (WBO:UCB) » Definitions » Purchase Of Investment

UCB (WBO:UCB) Purchase Of Investment : €-18 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is UCB Purchase Of Investment?

UCB's purchase of investment for the six months ended in Dec. 2023 was €-14 Mil. It means UCB spent €14 Mil on purchasing investments. UCB's purchase of investment for the trailing twelve months (TTM) ended in Dec. 2023 was €-18 Mil.

Compared with last quarter (€-4 Mil in Jun. 2023 ), UCB spent more money on purchasing investments in Dec. 2023 (€-14 Mil).

UCB Purchase Of Investment Historical Data

The historical data trend for UCB's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Purchase Of Investment Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.00 -7.00 -19.00 -17.00 -18.00

UCB Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.00 -7.00 -10.00 -4.00 -14.00

UCB Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of UCB's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB (WBO:UCB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (WBO:UCB) » Definitions » Purchase Of Investment
Comparable Companies
XBRU:ARGX XBRU:TUB XBRU:HYL XBRU:ONWD XBRU:ALIMG XBRU:CYAD XBRU:BIOS XBRU:OXUR OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 BNTX OCSE:GMAB ALNY BGNE BMRN
Traded in Other Exchanges
UCBJY:USA UCBJF:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Belgium
Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
Website
https://www.ucb.com
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (WBO:UCB) Headlines

No Headlines